Kinnate Biopharma - About the company
Kinnate Biopharma is an acquired company based in San Diego (United States), founded in 2018 by Eric Murphy and Steve Kaldor. It operates as a Developer of small molecule therapeutics for cancer treatment. Kinnate Biopharma has raised $172M in funding from investors like Orbimed, RA Capital Management and Nextech Invest. The company has 3384 active competitors, including 1127 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of small molecules therapeutics for cancer treatment. It offers drugs in 3 programs, precision oncology focused on DNA damage repair mechanisms, inhibitor targeting gene rearrangements with known resistance mutations, and inhibitor targeting a pathway clinically validated across all cancers.
- Website
- kinnate.com
- Email ID
- *****@kinnate.com
- Phone Number
- +1 **********
- Registered Address
- 12830 El Camino Real, Suite 150 San Diego, CA 92130
Key Metrics
Founded Year
2018
Location
San Diego, United States
Stage
Acquired
Total Funding
$172M in 2 rounds
Latest Funding Round
Ranked
628th among 3384 active competitors
Employee Count
10 - 49 as on Mar 01, 2026
Similar Companies
Exit Details
Acquired by XOMA Corporation (Feb 16, 2024)
Legal entities associated with Kinnate Biopharma
Kinnate Biopharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Kinnate Biopharma Inc. CIN: 82-4566526 , United States, Active | Jan 03, 2018 | - | 30 (As on Dec 31, 2020) | - |
Kinnate Biopharma's acquisition details
Kinnate Biopharma got acquired by XOMA Corporation on Feb 16, 2024.
Click here to take a look at Kinnate Biopharma's acquisition in detail
Sign up to download Kinnate Biopharma's company profile
Kinnate Biopharma's funding and investors
Kinnate Biopharma has raised a total funding of $172M over 2 rounds. Its first funding round was on Dec 12, 2019. Its latest funding round was a Series C round on Jul 21, 2020 for $*****. 13 investors participated in its latest round. Kinnate Biopharma has 17 institutional investors.
Here is the list of recent funding rounds of Kinnate Biopharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 21, 2020 | 9124735 | Series C | 4801101 | 2294847 | 5875208 | 1468060 |
Dec 12, 2019 | 6404774 | Series B | 4949393 | 7625420 |
Access funding benchmarks and valuations. Sign up today!View details of Kinnate Biopharma's funding rounds and investors
Kinnate Biopharma's founders and board of directors
Founder? Claim ProfileThe founders of Kinnate Biopharma are Eric Murphy and Steve Kaldor. Steve Kaldor is the CEO of Kinnate Biopharma.
Here are the details of Kinnate Biopharma's key team members:
- Eric Murphy: Co-Founder & CSO of Kinnate Biopharma.
- Steve Kaldor: Co-Founder & CEO of Kinnate Biopharma.
View details of Kinnate Biopharma's Founder profiles and Board Members
Kinnate Biopharma's employee count trend
Kinnate Biopharma has 10 - 49 employees as of Mar 26. Here is Kinnate Biopharma's employee count trend over the years:
Uncover Kinnate Biopharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Kinnate Biopharma's Competitors and alternates
Top competitors of Kinnate Biopharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Kinnate Biopharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
628th | Kinnate Biopharma 2018, San Diego (United States), Acquired | Developer of small molecule therapeutics for cancer treatment | $172M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Kinnate Biopharma's competitors? Click here to see the top ones
Kinnate Biopharma's Investments and acquisitions
Kinnate Biopharma has made no investments or acquisitions yet.
Reports related to Kinnate Biopharma
Here is the latest report on Kinnate Biopharma's sector:
News related to Kinnate Biopharma
Filter this list•
Halper Sadeh LLC Investigates LABP, FUSN, KNTEPR Newswire•Mar 26, 2024•Halper Sadeh, Kinnate Biopharma, Fusion Pharmaceuticals, Landos Biopharma
•
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.GlobeNewswire•Mar 20, 2024•XOMA Corporation, Kinnate Biopharma
•
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – TGAN, HMST, KNTEBenzinga•Mar 19, 2024•Monteverde, Transphorm, HomeStreet Bank, Kinnate Biopharma
•
Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTEPR Newswire•Mar 19, 2024•Halper Sadeh, Kinnate Biopharma, NGM Biopharmaceuticals, HireRight and 1 other
•
Halper Sadeh LLC Investigates KNTE, DOOR, HMSTBenzinga•Mar 14, 2024•Kinnate Biopharma, Masonite International, Halper Sadeh
•
The M&A Class Action Firm Continues Investigating the Merger – KNTE, DOOR, HMSTGlobeNewswire•Mar 14, 2024•Monteverde, Kinnate Biopharma, Masonite International, HomeStreet Bank
•
The M&A Class Action Firm Continues Investigating the Merger – HAYN, EVBG, TASTGlobeNewswire•Mar 14, 2024•Monteverde, Haynes International, Everbridge, Carrols and 2 others
•
The M&A Class Action Firm Continues Investigating the Merger – BATL, MDC, KNTE, INBXGlobeNewswire•Mar 07, 2024•Monteverde, Battalion Oil, Richmond American Homes, Kinnate Biopharma and 1 other
•
Pierre Fabre: Acquisition of the Pan-Raf experimental inhibitor of Kinnate BiopharmaMyPharma Editions•Mar 04, 2024•Kinnate Biopharma, Pierre Fabre
•
XOMA’s Acquisition of Kinnate BiopharmaGlobal Legal Chronicle•Feb 22, 2024•XOMA Corporation, Gibson, Kinnate Biopharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Kinnate Biopharma
Explore our recently published companies
- Bewegen voor je Brein - Hilversum based, 2019 founded, Unfunded company
- JufipAI - Arlington based, 2014 founded, Unfunded company
- Matchly - Unfunded company
- Contemplation Software - Cape Town based, 2024 founded, Unfunded company
- Tough Tongue AI - Unfunded company
- Classy Agent - 2020 founded, Unfunded company
